Brigham Hyde and the uses of a winding road

Brigham Hyde has occupied both sides of the table: the scientist’s bench and the investor’s chair. He has also discovered that neither quite satisfies the urge to build something. His career has taken him through a doctorate, equity research, a software startup, an acquisition, venture investing and the chief executive’s office. A straight line would have been easier to draw. It would have missed rather a lot.

Today he is co-founder and CEO of Atropos Health. The title is tidy; the route to it is less so. Look closely at the changes of occupation, however, and a recurring interest appears: making scattered information useful enough for someone to act on. The work has changed scale and setting. The question of what to do with the data has stayed with him.

There is a useful place to begin this story, before the current company and before the latest conversation about artificial intelligence. It is 2012, and Hyde is explaining a young software business by invoking a machine familiar to Wall Street. Relay Technology Management, he says, should become something like Bloomberg for its own industry. A scientist who has worked in finance is borrowing a financier’s reference point to explain a product. The career already makes a certain kind of sense.

A chemistry student takes the scenic route

Hyde graduated from Northeastern University in 2004, having studied chemistry. The university’s later alumni spotlight describes a combination of scientific interest and business instinct. It is an apt starting point for a career in which the two keep exchanging places. Chemistry provided a discipline to learn; business provided another set of questions about how knowledge might be put to work.

He went on to Tufts, completing his doctorate in 2009. His academic connections would continue beyond the degree, with an adjunct faculty role at Tufts and research faculty work at MIT Media Lab appearing in his professional biographies. The university world remained part of the picture even as his working life moved into companies.

Before Relay became his principal occupation, Hyde was an equity research analyst at Cowen & Company in Boston. That job placed him in the business of examining companies and their prospects. It is a different vantage point from running experiments, with a different audience waiting for the answer. Across those roles, he acquired experience producing research and interpreting it for people making financial decisions.

The move also gives his later fundraising conversations some texture. When Hyde talks about an investor’s expectations, he has done more than rehearse a pitch in front of one. He has worked inside finance. The founder arriving with the slides has previously had a reason to interrogate them.

Bloomberg, with a different audience

At Relay, where he was co-founder and eventually CEO, the ambition was to make information easier to compare. Its Business Development Live product brought together material from news services, scientific publications and other records. Users could examine assets, people and organizations through a common analytical system, rather than assemble the picture one document at a time.

The Bloomberg comparison was a revealing choice. It described an ambition for a shared working tool, something people would consult while doing business. Hyde was interested in how a field could organize its knowledge, establish comparisons and make decisions with a clearer view of the available information.

There was also a practical side to the software. Relay used Attivio’s technology to connect different kinds of information. In a 2014 account of the project, Hyde described building the infrastructure, incorporating the platform and getting the product ready in ten months. Some entrepreneurial achievements are expressed in unusually large numbers. This one was expressed in a calendar.

That detail is worth lingering over. A product launch depends on a series of choices about what to develop and what to obtain from elsewhere. Relay’s use of existing connectors was one such choice. The result was a tool a customer could use, assembled through a combination of original work and technology already available. Even early in his career, Hyde was discussing the machinery behind the ambition.

The acquisition changes the desk

On January 7, 2014, Decision Resources Group announced its acquisition of Relay Technology Management. The announcement paired Relay’s software and data capabilities with the larger organization’s research and analysis. For Hyde, the deal meant carrying the work into a different organizational setting.

He became chief data officer and senior vice president of analytics at DRG. By the time he appeared at the MIT Sloan CIO Symposium in 2015, those were the titles on his biography. The co-founder of a smaller company was now responsible for analytics within a larger one, serving customers through an established business.

Acquisition stories often end at the announcement. Hyde’s continued role supplies the next part: someone still has to make the combined offering useful. Software, information and analysts have to work together. His career at DRG belongs in the story because it adds operating experience after the transaction, when the attractive logic of a deal encounters the ordinary demands of delivery.

The investor also wants to operate

At Symphony AI, Hyde became a partner and led the investment in ConcertAI. He also helped found and operate the business, holding an operating role through its first three years. The combination matters. He was involved in choosing where capital would go and in the work that followed its arrival.

His next senior role was president of data and analytics at Eversana. Across these organizations, the recurring titles are founder, investor and operator. They describe different obligations. A founder establishes a direction. An investor evaluates the opportunity. An operator has to make the business function. Hyde’s résumé keeps putting him in more than one of those positions.

There is a temptation to turn such a career into a perfectly planned progression. His public account is more modest and more interesting: a scientist who spent time in finance and wanted to build. The succession of companies gave that inclination several outlets. The direction becomes visible across the jobs, without requiring a claim that every turn was mapped in advance.

“I promise it all makes sense somewhere in my head.”

Brigham Hyde, in conversation with Michelle Snyder, 2026

Backing the company, then taking the job

Hyde provided funding support for Atropos Health’s official launch in late 2020. His co-founders are Nigam Shah and Saurabh Gombar, and the business emerged from Stanford. He became CEO in August 2022. Once again, his involvement crossed the boundary between backing a venture and running it.

The interval between launch and appointment is a useful distinction. Supporting the creation of a business and taking responsibility as chief executive are separate commitments. Hyde made both. By then, he had already experienced the early stages of a startup, its sale, the operation of a larger analytics business and the investor’s role in another company.

In May 2024, Atropos announced a $33 million Series B led by Valtruis. New strategic investors included Cencora Ventures, McKesson Ventures and Merck Global Health Innovation Fund. Existing investors included Breyer Capital, Emerson Collective and Presidio Ventures. The financing brought a collection of investment firms and corporate partners around the same table.

An invitation to disagree

Hyde’s comments on leadership supply a more personal glimpse than the funding announcement. In a 2025 conversation alongside Ceremonia founder Babba Rivera, he described borrowing the idea of an R&D day from public companies. He brings investors and advisers into a discussion of products and everyday work, giving them something more specific to respond to than financial results.

The payoff, he said, can be an introduction to a customer or partner. It is a concrete way to ask a network to participate. Instead of leaving advisers with a general invitation to be helpful, the discussion gives them details they can connect to people they know. The product becomes the basis of the conversation.

He also values fellow founders and a group willing to offer conflicting views. That is a revealing preference in a chief executive. Advice becomes useful when it contains information the recipient did not already possess, including an objection. A room full of agreement may be pleasant company. It is less likely to expose a weak assumption before a customer does.

A return to Tufts

In 2026, Tufts named Hyde a Distinguished Achievement Award honoree. The recognition returned the story to the institution where he completed his doctorate seventeen years earlier. The intervening career had taken him well beyond an academic job description, through finance, software and the responsibilities of company leadership.

What makes the route interesting is the amount of overlap between its chapters. The analyst became a founder; the founder became an executive inside an acquiring company; the investor took on operating work. Each change gave him another position from which to examine what a business needs to succeed.

There is no shortage of new vocabulary in the companies around him. His own career can be described with rather older verbs: study, compare, build, invest, run. They are demanding enough. Atropos is the current setting for that work, and Hyde arrives there with experience of the people who fund a company, the people who make its products and the people who have to explain why any of it is useful.